Severino tapped to helm Amgen's global development team

Amgen ($AMGN) has tapped Michael Severino, M.D., as its new senior vice president, global development and chief medical officer. Severino, 46, formerly vice president, global development at Amgen, is replacing Sean Harper, who was recently named executive vice president, R&D. "Mike brings broad experience and immense expertise to his new role and I am confident that under his leadership, Amgen's global development team will continue to deliver important new medicines for patients with serious illnesses," said Harper. Release

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.